Back to top

gene-therapy: Archive

Zacks Equity Research

Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday

Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.

RHHBYPositive Net Change SRPTNegative Net Change CTMXNegative Net Change SLDBNegative Net Change

Zacks Equity Research

Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs

Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.

AZNNegative Net Change NVONegative Net Change LLYNegative Net Change OMGAPositive Net Change

Zacks Equity Research

Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study

Data from a late-stage study shows that non-transfusion-dependent thalassemia patients who received Agios' (AGIO) mitapivat demonstrated a statistically significant increase in hemoglobin response.

BMYNegative Net Change AGIONegative Net Change BLUENegative Net Change AQSTNegative Net Change

Zacks Equity Research

MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why

MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.

SNYNegative Net Change JNJPositive Net Change CTMXNegative Net Change MGTXPositive Net Change

Zacks Equity Research

Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why

Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.

VRTXPositive Net Change BLUENegative Net Change EDITNegative Net Change CRSPPositive Net Change